select a format

Single User License
USD 2000 INR 130060
Site License
USD 4000 INR 260120
Corporate User License
USD 6000 INR 390180


Request a quote
Request a Customized research
Request for Sample Report


Recent Viewed Reports

Why Ken Reasearch?


The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

Allergic Rhino-Conjunctivitis-Pipeline Review, H1 2015

Allergic Rhino-Conjunctivitis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6274IDB
  • |
  • Pages: 85
  • |
  • February 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Allergic Rhino-Conjunctivitis-Pipeline Review, H1 2015


Global Markets Direct's, 'Allergic Rhino-Conjunctivitis-Pipeline Review, H1 2015', provides an overview of the Allergic Rhino-Conjunctivitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Allergic Rhino-Conjunctivitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Allergic Rhino-Conjunctivitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Allergic Rhino-Conjunctivitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Allergic Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@]

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Allergic Rhino-Conjunctivitis Overview 8

Therapeutics Development 9

Pipeline Products for Allergic Rhino-Conjunctivitis-Overview 9

Pipeline Products for Allergic Rhino-Conjunctivitis-Comparative Analysis 10

Allergic Rhino-Conjunctivitis-Therapeutics under Development by Companies 11

Allergic Rhino-Conjunctivitis-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Allergic Rhino-Conjunctivitis-Products under Development by Companies 15

Allergic Rhino-Conjunctivitis-Companies Involved in Therapeutics Development 17

ALK-Abello A/S 17

Allergopharma Joachim Ganzer KG 18

Allergy Therapeutics plc 19

Anergis SA 20

Bial-Portela & Ca, S.A. 21

BioTech Tools s.a. 22

Circassia Pharmaceuticals plc 23

Greer Laboratories, Inc. 24

HAL Allergy BV 25

Immunomic Therapeutics, Inc. 26

Laboratorios LETI S.L. 27

Stallergenes S.A. 28

Allergic Rhino-Conjunctivitis-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Combination Products 30

Assessment by Target 31

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

Acaroid-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

AL-0704rP-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

ALK Birch Pollen Vaccine-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Allergovac-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

AllerT-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Avanz Phleum Pratense-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Depigoid Birch-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Dermatophagoides Pteronyssinus Allergen Extract-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

gpASIT + TM-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Grass Pollen Allergoid-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Grass-SPIRE-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

House Dust Mite-SPIRE-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

JRC2-LAMP-vax-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

MK-8237-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Olea Europaea Pollen Extract-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Pollinex Quattro Grass-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Ragweed Pollen Extract-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

rBet v1-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

rBet v1-FV-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

rPhleum-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Allergic Rhino-Conjunctivitis-Recent Pipeline Updates 68

Allergic Rhino-Conjunctivitis-Dormant Projects 76

Allergic Rhino-Conjunctivitis-Discontinued Products 77

Allergic Rhino-Conjunctivitis-Product Development Milestones 78

Featured News & Press Releases 78

Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen 78

May 18, 2014: BioTech Tools will be present at the EAACI congress 79

Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology 80

Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics 81

Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites 82

Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA 82

Appendix 84

Methodology 84

Coverage 84

Secondary Research 84

Primary Research 84

Expert Panel Validation 84

Contact Us 84

Disclaimer 85

List of Tables

Number of Products under Development for Allergic Rhino-Conjunctivitis, H1 2015 9

Number of Products under Development for Allergic Rhino-Conjunctivitis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Development by Companies, H1 2015 (Contd..1) 16

Allergic Rhino-Conjunctivitis-Pipeline by ALK-Abello A/S, H1 2015 17

Allergic Rhino-Conjunctivitis-Pipeline by Allergopharma Joachim Ganzer KG, H1 2015 18

Allergic Rhino-Conjunctivitis-Pipeline by Allergy Therapeutics plc, H1 2015 19

Allergic Rhino-Conjunctivitis-Pipeline by Anergis SA, H1 2015 20

Allergic Rhino-Conjunctivitis-Pipeline by Bial-Portela & Ca, S.A., H1 2015 21

Allergic Rhino-Conjunctivitis-Pipeline by BioTech Tools s.a., H1 2015 22

Allergic Rhino-Conjunctivitis-Pipeline by Circassia Pharmaceuticals plc, H1 2015 23

Allergic Rhino-Conjunctivitis-Pipeline by Greer Laboratories, Inc., H1 2015 24

Allergic Rhino-Conjunctivitis-Pipeline by HAL Allergy BV, H1 2015 25

Allergic Rhino-Conjunctivitis-Pipeline by Immunomic Therapeutics, Inc., H1 2015 26

Allergic Rhino-Conjunctivitis-Pipeline by Laboratorios LETI S.L., H1 2015 27

Allergic Rhino-Conjunctivitis-Pipeline by Stallergenes S.A., H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Assessment by Combination Products, H1 2015 30

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Route of Administration, H1 2015 33

Number of Products by Stage and Molecule Type, H1 2015 35

Allergic Rhino-Conjunctivitis Therapeutics-Recent Pipeline Updates, H1 2015 68

Allergic Rhino-Conjunctivitis-Dormant Projects, H1 2015 76

Allergic Rhino-Conjunctivitis-Discontinued Products, H1 2015 77

List of Figures

Number of Products under Development for Allergic Rhino-Conjunctivitis, H1 2015 9

Number of Products under Development for Allergic Rhino-Conjunctivitis-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Routes of Administration, H1 2015 32

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 33

Number of Products by Top 10 Molecule Types, H1 2015 34

Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

ALK-Abello A/S

Allergopharma Joachim Ganzer KG

Allergy Therapeutics plc

Anergis SA

Bial - Portela & Ca, S.A.

BioTech Tools s.a.

Circassia Pharmaceuticals plc

Greer Laboratories, Inc.

HAL Allergy BV

Immunomic Therapeutics, Inc.

Laboratorios LETI S.L.

Stallergenes S.A.

Allergic Rhino-Conjunctivitis Therapeutic Products under Development, Key Players in Allergic Rhino-Conjunctivitis Therapeutics, Allergic Rhino-Conjunctivitis Pipeline Overview, Allergic Rhino-Conjunctivitis Pipeline, Allergic Rhino-Conjunctivitis Pipeline Assessment

Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]